垂体腺瘤神经解剖结构辐射剂量与伽玛刀对垂体功能的影响
该回顾性研究纳入1998至2015年接受伽玛刀放射外科治疗的236例垂体腺瘤患者,对下丘脑、垂体柄和正常垂体进行点剂量测量,分析剂量与内分泌结局的关系。中位随访42.9个月,18.6%出现新发垂体功能减退,垂体柄与正常腺体剂量比≥0.8显著增加内分泌病风险。
要点
- 伽玛刀治疗垂体腺瘤后新发垂体功能减退率较低,中位随访42.9个月为18.6%。
- 垂体柄与正常腺体剂量比≥0.8显著增加内分泌病风险。
- 下丘脑剂量普遍较低,一般不预示内分泌缺陷。
核心结论
- 伽玛刀放射外科治疗垂体腺瘤的迟发性垂体功能不全发生率低。
- 下丘脑剂量低且一般不预示内分泌缺陷。
- 垂体柄相对正常腺体接受高剂量者术后内分泌病风险更高。
- 垂体柄与腺体剂量比≥0.8显著增加伽玛刀术后内分泌病风险。
研究设计与样本
- 回顾性队列研究,纳入1998至2015年接受伽玛刀放射外科治疗的236例垂体腺瘤患者。
- 41.5%为非功能性腺瘤,58.5%为功能性腺瘤。
- 对下丘脑双侧、垂体柄和正常垂体的14个一致点进行点剂量测量,无最小体积要求。
主要发现
- 中位随访42.9个月,18.6%患者出现新发垂体功能丧失。
- 内分泌病中位发生时间为21个月(范围2-157个月)。
- 下丘脑中位剂量2.1 Gy,垂体柄中位剂量9.1 Gy,正常垂体中位剂量15.3 Gy。
- 多因素分析中,年龄增加(p=0.015,HR 0.98)和垂体柄最大剂量与正常腺体剂量比(p=0.013,HR 0.22)是新发或加重垂体功能减退的独立预测因素。
- 性别、边缘剂量、治疗体积、非功能性腺瘤状态或垂体柄与下丘脑剂量比不是显著预测因素。
关键数值与推荐
- 垂体柄与正常腺体辐射剂量比≥0.8显著增加伽玛刀术后内分泌病风险。
临床怎么用
- 伽玛刀治疗垂体腺瘤时应关注垂体柄与正常腺体的剂量比,比值≥0.8时内分泌病风险增加。
- 改善朝向垂体柄和正常腺体的梯度指数可能有助于保护内分泌功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gamma Knife radiosurgery (GKRS) provides a safe and effective management option for patients with all types of pituitary adenomas. The long-term adverse effects of targeted radiation to the hypothalamic-pituitary axis in relationship to radiation dose remain unclear. In this retrospective review, the authors investigated the role of differential radiation doses in predicting long-term clinical outcomes and pituitary function after GKRS for pituitary adenomas. METHODS: A cohort of 236 patients with pituitary tumors (41.5% nonfunctioning, 58.5% functioning adenomas) was treated with GKRS between 1998 and 2015. Point dosimetric measurements, with no minimum volume, to 14 consistent points along the hypothalamus bilaterally, pituitary stalk, and normal pituitary were made. Statistical analyses were performed to determine the impact of doses to critical structures on clinical, radiological, and endocrine outcomes. RESULTS: With a median follow-up duration of 42.9 months, 18.6% of patients developed new loss of pituitary function. The median time to endocrinopathy was 21 months (range 2-157 months). The median dose was 2.1 Gy to the hypothalamus, 9.1 Gy to the pituitary stalk, and 15.3 Gy to the normal pituitary. Increasing age (p = 0.015, HR 0.98) and ratio of maximum dose to the pituitary stalk over the normal pituitary gland (p = 0.013, HR 0.22) were independent predictors of new or worsening hypopituitarism in the multivariate analysis. Sex, margin dose, treatment volume, nonfunctioning adenoma status, or ratio between doses to the pituitary stalk and hypothalamus were not significant predictors. CONCLUSIONS: GKRS offers a low rate of delayed pituitary insufficiency for pituitary adenomas. Doses to the hypothalamus are low and generally do not portend endocrine deficits. Patients who are treated with a high dose to the pituitary stalk relative to the normal gland are at higher risk of post-GKRS endocrinopathy. Point dosimetry to specific neuroanatomical structures revealed that a ratio of stalk-to-gland radiation dose of 0.8 or more significantly increased the risk of endocrinopathy following GKRS. Improvement in the gradient index toward the stalk and normal gland may help preserve endocrine function.
引用
- Pomeraniec IJ, Taylor DG, Cohen-Inbar O, et al. Radiation dose to neuroanatomical structures of pituitary adenomas and the effect of Gamma Knife radiosurgery on pituitary function. J Neurosurg. 2019. PMID: 30978685. doi:10.3171/2019.1.JNS182296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。